Please login to the form below
Orchard Therapeutics
This page shows the latest Orchard Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Bicycle Therapeutics looks to raise $86m with IPO
Key data readout expected later this year. UK biotech company Bicycle Therapeutics is to launch an IPO via the US Nasdaq exchange to raise $86.25m. ... In November last year, gene therapy specialist Orchard Therapeutics raised over $200m, while CAR-T
Latest news
-
Investments show UK biotech still booming despite Brexit
One such company was London-headquartered firm Orchard Therapeutics, which successfully raised $200m in November.
-
J&J bolsters gene therapy unit with $100m MeiraGTx deal
GlaxoSmithKline launched its Strimvelis product in 2016, but sold it to Orchard Therapeutics last year after opting to exit the rare disease category. ... The US market developed a little later, with Spark Therapeutics’ Luxturna (voretigene neparvovec)
-
UK biotech booms in 2018, despite Brexit worries
Industry attracted a record-breaking £2.2bn in investment last year
-
MedCity sets up advanced therapy research network
UK companies operating int his area include university spinouts Orchard Therapeutics, Autolus, Cell Medica, GammaDelta and Quethera.
-
Orchard surpasses IPO expectations, raising $200m
Funds will progress rare disease portfolio. Orchard Therapeutics, the UK-based gene therapy company, launched on Nasdaq late last week, raising $200m from an IPO. ... Orchard also has plans to open a US manufacturing facility within the next few years,
More from news
Approximately 6 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Bluebird Bio: on the cusp of a gene therapy revolution
drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... GSK has also had very limited success with Strimvelis and has now sold on the treatment to UK-based gene
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team
Orchard Therapeutics expands leadership team. Gene therapy focused Orchard Therapeutics has announced two new additions to its executive leadership team. ... She joins Orchard from AMAG Pharmaceuticals, where she served as senior vice president,
-
Orchard Therapeutics appoints Mark Rothera as CEO
He joins from PTC Therapeutics. London, UK-based Orchard Therapeutics has appointed Mark Rothera as its new president and chief executive officer at a time when the group progresses its clinical ... He said: “Now is an exciting time to be joining
More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
Reflections of a Fireside Chat from the World Orphan Drug Congress 2020
The result was Orchard Therapeutics, a company dedicated to setting up a process that enables the treatment cells to travel so that patients, who are already living with debilitating diseases, do ... As a business, Orchard Therapeutics want to introduce
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
